I quickly found out that a new rights issue is on the way. For every current share, you would receive 4 new shares. And the price, if you then buy/exercise them, would be 0.01 SEK/share.
3 Likes
I follow it every now and then. I own a small position - and based on the share price development and having read the last couple of interim reports, I don’t dare to put more money into this.
Reason: In 2022, they said the company would break even in 2024.
Since then, there have been repeated share issues, and now the story is that cash flow would be positive in the second half of 2025.
In 2021, they acquired a company called Common Sense from Israel. A moment ago, they announced its shutdown and gave cost reduction as the reason? Does anyone remember/can find the purchase price? It seems, however, that a loss was incurred.
And are those gels applied to the labia and vaginal area really that special after all?
The company hyped up a lot in 2023 how they are expanding distribution to Central and South America, but this year no hype has been heard. I wonder why?
Eh. Good luck to everyone who has put their money into this. I’m just waiting to sell some other stock so I can get out of this tracking position. I no longer believe in this company’s future. I’ll look into it again when they achieve a profitable result for at least two consecutive quarters.
1 Like
STOCKHOLM (Nyhetsbyrån Direkt) Medtech company Peptonic Medical has decided to file an application for corporate restructuring.
“The decision is an extraordinary measure due to a long-term strained liquidity situation and aims to create conditions for a stable and profitable business. External consultants have evaluated the situation and assessed that Peptonic has good chances of being granted reconstruction,” the company writes in a press release.
Via Google Translate: STOCKHOLM (Nyhetsbyrån Direkt) Lääketieteen teknologiayritys Peptonic Medical on päättänyt jättää hakemuksen yrityssaneeraukseen. “Päätös on poikkeuksellinen toimenpide, joka johtuu pitkäaikaisen paineen aiheuttamasta likviditeettitilanteesta ja sen tavoitteena on luoda edellytykset vakaalle ja kannattavalle toiminnalle. Ulkopuoliset konsultit ovat arvioineet tilanteen ja arvioineet, että Peptonicilla on hyvät mahdollisuudet saada uudelleenjärjestely”, yhtiö kirjoittaa tiedotteessa.
2 Likes
Is anyone still following this company?
Today, 25% of the shares have changed hands, and there was apparently some good news this morning as well.
AI summary of it:
Peptonic Medical AB reports it is close to the first product delivery as part of its collaboration agreement with a US-based player focused on women’s intimate wellness. The agreement covers the United States, Canada, Mexico, and the United Kingdom, and the products will be sold under the partner’s well-known brand.
The first order, valued at approximately $120,000, was received in October 2025. Product design and delivery preparations have progressed as planned, and the first delivery is seen as an important milestone in Peptonic’s international growth strategy.
Interim CEO Daniel Rudeklint emphasized that the collaboration strengthens the company’s opportunities to grow internationally through partnerships and to reach more women with science-based intimate care products.
2 Likes